Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Lilly and Pfizer ... Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

are the first related to copycat tirzepatide since the U.S. Food and Drug Administration took the drug off its list of medicines in short supply earlier this month. Lilly said these lawsuits ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

A turbulent series of events surrounding the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the Food and Drug Administration maintains its list of drug ...

Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...

Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform— Demonstration of the ...